Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 43NIH 4NETWORK 4INDUSTRY 3FED 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Adenomatous Polyposis Coli 2Breast Neoplasms 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Celecoxib × Clear all
NCT00151476 2024-09-04

Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients

Pfizer

Terminated
68 enrolled 22 charts
Gastrointestinal

Adenomatous Polyposis Coli

NCT00585312 2021-02-21

CHIP

Pfizer

Phase 3 Terminated
106 enrolled 10 charts
Gastrointestinal

Adenomatous Polyposis Coli

NCT00038103 2010-02-25

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

Pfizer

Phase 2 Completed
111 enrolled 14 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡